

# The effect of interrupting sitting with regular active breaks on vascular function in adults with type 1 diabetes

<b>Submission date</b> 29/07/2025	<b>Recruitment status</b> Recruiting	<input checked="" type="checkbox"/> Prospectively registered
		<input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 05/08/2025	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 30/07/2025	<b>Condition category</b> Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Individual participant data
		<input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

People with type 1 diabetes (T1D) are advised to stay physically active to help manage their blood sugar and reduce the risk of heart disease. However, many people with T1D spend long periods sitting during the day — for example, while working or watching TV. New research suggests that sitting for long stretches could affect blood flow and increase the risk of health problems, even in people who are otherwise active. This study will look at how long periods of sitting, compared with sitting that is regularly interrupted with short bouts of light walking, affect blood sugar and blood vessel function in adults with T1D who use a hybrid closed-loop (HCL) insulin delivery system. These systems automatically adjust insulin delivery in response to blood glucose. The aim of the study is to find out whether breaking up sitting time improves glucose levels, reduces inflammation, and helps blood vessel function.

### Who can participate?

Patients aged 18 or older who have had type 1 diabetes for more than 3 years and use a hybrid closed-loop insulin delivery system

### What does the study involve?

Each participant will take part in two separate 7-hour sessions in a laboratory. The sessions will be spaced at least four days apart, and the order will be random. In one session, participants will sit for the full 7 hours without interruption. In the other, they will break up their sitting every 30 minutes with a 3-minute light walk.

#### Before each visit:

- Participants will wear a small physical activity monitor (called activPAL4) for 48 hours
- They will record their meals using a free app (MyFitnessPal)
- Standardised meals will be provided to eat the night before and morning of the visit
- They will continue using their continuous glucose monitor (CGM) and insulin pump

#### During the lab visits:

- Blood vessel health will be measured using ultrasound scans
- Blood pressure and heart rate will be recorded
- Brain blood flow will be monitored using an ultrasound of the head and neck

- Blood samples will be taken to measure inflammation markers (such as interleukin-6 and VCAM-1)
  - Glucose levels and insulin use will be tracked continuously using the participant's own devices
- After each visit:

- Participants will wear the activity monitor for another 48 hours
- They will continue to record their meals and glucose levels

The main outcome will be a measure of blood vessel function in the leg (called flow-mediated dilation). Other outcomes include blood glucose trends, brain blood flow, and inflammatory markers.

What are the possible benefits and risks of participating?

Participants will help researchers understand how sitting and light movement affect blood sugar and blood vessel health in people with type 1 diabetes.

There are no expected direct health benefits for participants. Risks are low but include discomfort from wearing activity monitors and mild side effects from blood pressure cuffs or blood draws. Blood sugar will be closely monitored throughout, and fast-acting carbohydrates will be given if levels fall too low.

Where is the study run from?

The study is being run by the University of Birmingham, in collaboration with:

- Liverpool John Moores University (LJMU)
- Manchester Metropolitan University (MMU)

Testing will take place in university research laboratories at all three sites.

When is the study starting and how long is it expected to run for?

October 2024 to April 2027. Recruitment will run for 18 months.

Who is funding the study?

The University of Birmingham, UK

Who is the main contact?

Dr Katie Hesketh, Principal Investigator, [k.hesketh@bham.ac.uk](mailto:k.hesketh@bham.ac.uk)

## Contact information

### Type(s)

Public, Scientific

### Contact name

Mr Joseph Jenkins

### ORCID ID

<https://orcid.org/0009-0007-1365-4862>

### Contact details

School of Sport, Exercise and Rehabilitation Sciences (Y14),  
University of Birmingham  
Birmingham  
United Kingdom

B15 2TT  
+447397007217  
jgj301@student.bham.ac.uk

### **Type(s)**

Principal investigator

### **Contact name**

Dr Katie Hesketh

### **Contact details**

School of Sport, Exercise and Rehabilitation Sciences (Y14),  
University of Birmingham  
Birmingham  
United Kingdom  
B152TT  
+447906847159  
k.l.hesketh@bham.ac.uk

## **Additional identifiers**

### **Clinical Trials Information System (CTIS)**

Nil known

### **Integrated Research Application System (IRAS)**

338230

### **ClinicalTrials.gov (NCT)**

Nil known

### **Protocol serial number**

Protocol number: RG\_24-066

## **Study information**

### **Scientific Title**

Acute effect of breaking up sitting on peripheral and cerebral blood flow in adults with type 1 diabetes using closed-loop systems insulin systems

### **Study objectives**

The primary aim of this research is to investigate the influence of breaking up prolonged sitting with scheduled active breaks on peripheral vascular function, as measured by superficial femoral artery flow-mediated dilation (FMD), in adults with T1D who use HCL systems.

The secondary aims include investigating the impact of scheduled active breaks on peripheral blood flow (superficial femoral artery blood flow and shear rate), cerebral vascular function, continuous glucose monitor (CGM) derived endpoints (as outlined in the most recent consensus (Battelino et al., 2019)), insulin dose and serum concentrations of endothelin-1 (ET-1), vascular cellular adhesion molecule concentrations (VCAM-1), intracellular adhesion molecule (ICAM-1) and interleukin-6 (IL-6).

## **Ethics approval required**

Ethics approval required

## **Ethics approval(s)**

approved 11/02/2025, London - City & East Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 (0)207 1048171; cityandeast.rec@hra.nhs.uk), ref: 25/PR/0098

## **Study design**

Interventional randomized crossover trial

## **Primary study design**

Interventional

## **Study type(s)**

Treatment

## **Health condition(s) or problem(s) studied**

Improvement of vascular health in people with type 1 diabetes.

## **Interventions**

The study will use a randomised, crossover design, in which participants will complete two 7-hour experimental conditions, each separated by at least 4 days. One condition will involve participants sitting uninterrupted for 7 hours (sedentary), while the other will involve participants breaking up 7 hours of sitting with 3 minutes of low-intensity walking every 30 minutes (active breaks).

The order of the two trials will be randomised and counterbalanced using a computer-generated random allocation sequence ([www.randomization.com](http://www.randomization.com)). Due to the nature of the study, blinding of the participants or researchers is not possible. However, participants and researchers will be blinded to experimental condition order (by keeping the order in a sealed envelope) until 07:00 on the morning of the first experimental visit.

## **Intervention Type**

Behavioural

## **Primary outcome(s)**

Peripheral vascular function, as measured by superficial femoral artery flow-mediated dilation at pre-intervention (0h) and post-intervention (7h)

## **Key secondary outcome(s)**

1. Peripheral blood flow as measured by superficial femoral artery blood flow and shear rate at pre-intervention (0h) and post-intervention (7h)
2. Cerebral blood flow as measured by common carotid artery and internal carotid artery blood flow at pre-intervention (0h) and post-intervention (7h)
3. Cerebral vascular function as measured by middle cerebral artery blood velocity and CO<sub>2</sub> reactivity at pre-intervention (0h) and post-intervention (7h)
4. Blood pressure as measured using automated resting blood pressure measurement at pre-intervention (0h), 1.75h, 3.5h, 5.25h and post-intervention (7h)
5. Heart rate measured using continuous heart rate monitoring throughout the intervention
6. Markers of glycaemia as measured using a continuous glucose monitor time in range (3.9–10.0

mmol/L) measured via, mean glucose, % time in hypoglycaemia (<3.0 and 3.0–3.9 mmol/L), % time in hyperglycaemia (10.0–13.9 and >13.9 mmol/L), glycaemic variability hypoglycaemia /hyperglycaemia episodes, area under the curve measured

7. Insulin dose as measured using an insulin log of a closed-loop insulin pump, the mean insulin dose of the intervention

8. Serum markers of vascular function as measured using endothelin 1 concentrations, vascular cellular adhesion molecule 1 concentrations, intracellular adhesion molecule 1 concentrations, interleukin-6 concentrations at pre-intervention (0h) and post-intervention (7h)

### **Completion date**

01/04/2027

## **Eligibility**

### **Key inclusion criteria**

1. Having been diagnosed with T1D for more than 3 years
2. Aged 18-66 years
3. Not currently meeting physical activity guidelines of > 150 min/week of moderate-intensity exercise or >75 min/week of high-intensity exercise
4. Are sedentary (normally spend more than 5h per day sitting or lying down)
5. Use a closed-loop insulin delivery system

### **Participant type(s)**

Patient

### **Healthy volunteers allowed**

No

### **Age group**

Adult

### **Lower age limit**

18 years

### **Upper age limit**

66 years

### **Sex**

All

### **Total final enrolment**

30

### **Key exclusion criteria**

1. Pregnant or planning to become pregnant
2. <6 months postpartum or stopped breastfeeding <1 month before recruitment
3. Having been diagnosed with cerebrovascular or cardiovascular disease
4. Having a significant history of uncontrolled hyperglycaemia (HbA1c >85 mmol/L)

5. Having a history of severe hypoglycaemia requiring third-party assistance within the last 3 months

6. Cold or flu within the last 2 weeks

**Date of first enrolment**

01/10/2025

**Date of final enrolment**

01/03/2027

## **Locations**

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

**University of Birmingham**

School of Sport, Exercise and Rehabilitation Sciences, Y14, Edgbaston

Birmingham

United Kingdom

B15 2TT

**Study participating centre**

**Liverpool John Moores University**

School Of Sport & Exercise Science, Floor 0, City campus

Liverpool

United Kingdom

L3 5UX

**Study participating centre**

**Manchester Metropolitan University**

Department of Sport and Exercise Sciences

Ormond Building

Manchester

United Kingdom

M15 6BX

## **Sponsor information**

**Organisation**

University of Birmingham

**ROR**

<https://ror.org/03angcq70>

## **Funder(s)**

**Funder type**

University/education

**Funder Name**

University of Birmingham

**Alternative Name(s)**

**Funding Body Type**

Private sector organisation

**Funding Body Subtype**

Universities (academic only)

**Location**

United Kingdom

## **Results and Publications**

**Individual participant data (IPD) sharing plan**

The datasets generated during and/or analysed during the current study will be available upon request from the Principal Investigator, Dr Katie Hesketh, [k.l.hesketh@bham.ac.uk](mailto:k.l.hesketh@bham.ac.uk).

The type of data that will be shared: Data that underlie the results reported, after deidentification (text, tables, figures, and appendices).

Timing for availability: Beginning 3 months and ending 5 years following article publication.

Whether consent from participants was required and obtained: Consent from participants will be required and obtained to access this data

Comments on data anonymization: All files will be pseudonymised at the time of collection and will remain pseudonymised.

**IPD sharing plan summary**

Available on request

**Study outputs**

<b>Output type</b>	<b>Details</b>	<b>Date created</b>	<b>Date added</b>	<b>Peer reviewed?</b>	<b>Patient-facing?</b>
<a href="#">Participant information sheet</a>	version 2	10/02/2025	30/07/2025	No	Yes
<a href="#">Protocol file</a>	version 2	10/02/2025	30/07/2025	No	No